In this issue:
First-line pembrolizumab in Black patients with metastatic NSCLC
Radiomics predicts cachexia risk in ICI-treated advanced NSCLC
Clinical decision support algorithm to assess anti-PD-L1 response in NSCLC
Intracranial efficacy of selpercatinib in RET fusion-positive NSCLC
Nivolumab + carboplatin/paclitaxel/ bevacizumab for advanced nonsquamous NSCLC
Tepotinib in NSCLC harbouring MET exon 14 skipping
Tislelizumab + chemo for locally advanced or metastatic nonsquamous NSCLC
Nab-paclitaxel vs. docetaxel for previously treated advanced NSCLC
Three trials of rovalpituzumab tesirine in extensive-stage SCLC: second-line, + ICI and maintenance
Please login below to download this issue (PDF)